TCL-307 Epidemiological Data on T-Cell Lymphoma in the Republic of Kosovo During the Period of 2016-2021.

Abstract

T-cell lymphomas consist of a wide variety of uncommon diseases that can be indolent or aggressive and consists of 12% of all NHL. T-cell lymphoma is an uncommon hematological malignancy in Kosovo compared to the other lymphoid malignancies. There are a variety of subtypes of the disease present with anaplastic large T-cell lymphoma being the most common. The diagnosis of this disease has increased in the last few years and the treatment with chemotherapy and other supportive care has many challenges. With this study, we want to better understand the disease so we can improve the quality of care for the patients. Cross-sectional retrospective epidemiological study. The data was collected during the period of February 2016 to January 2021. The data was collected from the chemotherapy treatment protocol books and patient files in the Hematology Clinic of the University Clinical Center of Kosovo. Adults, age 18 and older, of both genders, diagnosed the treated with T-cell lymphoma in the Hematology clinic of Kosovo. The diagnosis was made based on histopathological and immunohistochemical analysis of lymphoid tissue mostly in the Republic of Kosovo. During the period specified above, 47 patients were diagnosed and treated with T-cell lymphoma, the most common was anaplastic large T-cell lymphoma with 11(23.40%) then enteropathy associated T-cell lymphoma with 8(17.02%), NK/T-cell lymphoma with 5(10.63%). One rare example of T-cell lymphoma was a patient diagnosed with gamma/delta T-cell lymphoma, which was the only such case in our clinic. Of the patients diagnosed with T-cell lymphoma during this period, 33 were treated with the CHOP protocol as first-line chemotherapy. The majority of patients were treated with the CHOP chemotherapy protocol as the first-line therapy. The results of the treatments were successful in achieving remissions in a small number of patients. The patients that did not achieve remission received a second treatment protocol with mixed results.